ACADIA Pharmaceuticals Appoints Steve Davis as Chief Executive Officer
September 03 2015 - 07:01AM
Business Wire
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical
company focused on the development and commercialization of
innovative medicines to address unmet medical needs in central
nervous system disorders, today announced that its Board of
Directors has appointed Steve Davis as President and Chief
Executive Officer. Mr. Davis has been serving as ACADIA’s Interim
Chief Executive Officer since March 2015. Mr. Davis has also been
appointed to the ACADIA Board of Directors.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20150903005511/en/
Steve Davis, Chief Executive Officer of
ACADIA Pharmaceuticals (Photo: Business Wire)
“We are delighted that Steve is our Chief Executive Officer,”
said Leslie L. Iversen, Ph.D., ACADIA’s Chairman of the Board. “He
is an accomplished leader and since joining ACADIA, Steve has done
a tremendous job of aligning ACADIA’s operations with our
short-term and long-term goals, continuing the build-out of our
capabilities, and positioning the Company for strong growth. I have
great confidence in Steve leading ACADIA through our next stage of
growth as we bring innovative treatments such as NUPLAZID™ to CNS
disease states with high unmet medical needs.”
“With Breakthrough Therapy designation and our submission of the
New Drug Application for NUPLAZID for Parkinson’s disease
psychosis, we have an opportunity to transform the treatment of
psychosis and significantly improve the lives of these patients,”
said Steve Davis, ACADIA’s Chief Executive Officer. “We are
building on our momentum as we prepare for the expected launch of
NUPLAZID in the United States and continue our efforts to explore
the full potential of NUPLAZID to treat patients suffering from
additional CNS disorders.”
Mr. Davis brings over 20 years of executive-level experience in
the pharmaceutical industry and more than 20 years of experience on
the boards of directors of publicly held biopharmaceutical
companies. He joined ACADIA in July 2014 as Executive Vice
President, Chief Financial Officer and Chief Business Officer and
was appointed Interim Chief Executive Officer in March 2015.
Previously, Mr. Davis served as Executive Vice President and Chief
Operating Officer at Heron Therapeutics, Inc., Executive Vice
President and Chief Operating Officer at Ardea Biosciences, Inc.,
and in numerous executive roles at Neurogen Corporation, including
Chief Executive Officer. Mr. Davis currently serves on the Board of
Directors of Bellicum Pharmaceuticals, Inc. He also recently served
on the boards of directors of Synageva BioPharma Corp., Heron
Therapeutics, and Furiex Pharmaceuticals, Inc.
Early in his career, Mr. Davis practiced as a Certified Public
Accountant with a major accounting firm and as a corporate and
securities attorney with a Wall Street law firm. Mr. Davis received
his Bachelor of Science degree in Accounting from Southern Nazarene
University and a J.D. from Vanderbilt University.
Separately, ACADIA issued a news release today announcing that
it has submitted a New Drug Application (NDA) to the U.S. Food and
Drug Administration (FDA) seeking approval for NUPLAZID
(pimavanserin) for the treatment of psychosis associated with
Parkinson’s disease.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development
and commercialization of innovative medicines to address unmet
medical needs in central nervous system disorders. ACADIA has a
pipeline of product candidates led by NUPLAZID™ (pimavanserin), for
which we have submitted a New Drug Application in Parkinson’s
disease psychosis to the FDA and which has the potential to be the
first drug approved in the United States for this condition.
Pimavanserin is also in Phase II development for Alzheimer’s
disease psychosis and has successfully completed a Phase II trial
in schizophrenia. ACADIA also has clinical-stage programs for
chronic pain and glaucoma in collaboration with Allergan, Inc. All
product candidates are small molecules that emanate from internal
discoveries. ACADIA maintains a website at www.acadia-pharm.com to
which we regularly post copies of our press releases as well as
additional information and through which interested parties can
subscribe to receive e-mail alerts.
Forward-Looking Statements
Statements in this press release that are not strictly
historical in nature are forward-looking statements. These
statements include but are not limited to statements related to
ACADIA’s positioning for strong growth; ACADIA’s ability to bring
innovative treatments such as NUPLAZID to CNS disease states with
high unmet medical needs; the potential for NUPLAZID (pimavanserin)
to be the first drug approved in the United States for Parkinson’s
disease psychosis (PDP), if approved at all, and the expected
launch of NUPLAZID for PDP; ACADIA’s opportunity to transform the
treatment of psychosis and significantly improve the lives of
patients with PDP with NUPLAZID; the potential of NUPLAZID to treat
patients suffering from CNS disorders other than PDP; and the
progress, timing and results of ACADIA’s drug discovery and
development programs, either alone or with a partner, including the
progress and expected timing of clinical trials. These statements
are only predictions based on current information and expectations
and involve a number of risks and uncertainties. Actual events or
results may differ materially from those projected in any of such
statements due to various factors, including the risks and
uncertainties inherent in drug discovery, development, approval and
commercialization, and in collaborations with others, and the fact
that past results of clinical trials may not be indicative of
future trial results. For a discussion of these and other factors,
please refer to ACADIA’s annual report on Form 10-K for the year
ended December 31, 2014 as well as ACADIA’s subsequent filings
with the Securities and Exchange Commission. You are cautioned not
to place undue reliance on these forward-looking statements, which
speak only as of the date hereof. This caution is made under the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. All forward-looking statements are qualified in their
entirety by this cautionary statement and ACADIA undertakes no
obligation to revise or update this press release to reflect events
or circumstances after the date hereof, except as required by
law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150903005511/en/
Investor Contacts:ACADIA Pharmaceuticals Inc.Steve Davis, Chief
Executive OfficerLisa Barthelemy, Director of Investor
Relations(858) 558-2871orMedia Contact:Russo PartnersDavid
Schull(212) 845-4271 or (858)
717-2310david.schull@russopartnersllc.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Feb 2024 to Mar 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Mar 2023 to Mar 2024